Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I know ;)
Agreed … quiet .. just adding a little morning humor … and I’m still drinking that first coffee yet … yawn .. lol
Good morning … perhaps it’s quiet because folks are still sleeping ;~)
It’s 2 1/2 hours yet before the morning bell
Still working on my first cup of coffee
… here’s to a good day ahead
https://vimeo.com/580475668
Great information… lots of topics covered
… ok, I wasn’t going to post this but .. Mercury is no longer retrograde … Astrology can be scoffed at or followed .. but regardless… whenever you hear “Mercury retrograde” those that do follow avoid communication & contracts … sooo for what it’s worth … since the otc market has definitely been bizarre as of late … if nothing else, perhaps this will help our end of October bode well bringing us now treats in lieu of tricks!
Qnta $$
“Not only will Mercury come out of retrograde, but heavy hitters Jupiter, Pluto and Saturn will too”
Good morning QNTA
One Reminder why I’m long here;
the Polarization patent $$$
$$ MedolifeRx AELIA imunapen QNTA $$
https://ir.quantrx.com/news-events/press-releases/detail/92/medolife-rx-reports-257-increase-in-efficacy-of-ibuprofen
{“It only makes sense that Escozine® would be effective in mitigating side
effects of COVID-19 vaccines as it has been proven to be effective in treating
or diminishing the symptoms of the COVID-19 virus itself,” said Medolife CEO
Dr. Arthur Mikaelian. “Specifically in the DR, and in many places around the
world, vaccine hesitancy is becoming more common for a multitude of reasons,
including the side effects associated with them.”}
Quanta, Inc.: Medolife Rx Clinical Observations Demonstrates Effectiveness of Escozine in Complementary Use with COVID-19
July 8, 2021, 8:30 AM EDT
BURBANK, Calif., July 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife
Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D,
manufacturing, and consumer product distribution, which is a majority owned
subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today new clinical
observations made on its lead drug candidate Escozine®.
Physicians observed that patients who originally had strong adverse reactions
to COVID-19 vaccines and who were given Escozine®, experienced significantly
lessened side effects. Typical vaccine side effects are similar to symptoms of
the actual COVID-19 virus, including body cough, aches, fatigue and fever,
among others.
These observations have led the Company to move forward with pursuing an
additional pilot study on the drug, looking to prove its effectiveness in
decreasing side effects of vaccinations for COVID-19. Management plans to meet
with the Ministry of Health and the office of the President of the DR to
present the observations and seek further guidance on next steps for approval
as a complimentary product for vaccine recipients.
“It only makes sense that Escozine® would be effective in mitigating side
effects of COVID-19 vaccines as it has been proven to be effective in treating
or diminishing the symptoms of the COVID-19 virus itself,” said Medolife CEO
Dr. Arthur Mikaelian. “Specifically in the DR, and in many places around the
world, vaccine hesitancy is becoming more common for a multitude of reasons,
including the side effects associated with them. While the idea of pursuing
Escozine® as a complementary product to COVID-19 vaccines was not originally
included in our study parameters, we plan to quickly initiate a pilot study in
order to prove its potential effectiveness as such. If we are able to do so,
Escozine® could have global applications as a complementary medicine,
decreasing the severity of side effects of COVID-19 vaccines, and hopefully,
decreasing vaccine hesitancy in patients with a high side effect risk rate.”
The Company is currently pursuing approval of Escozine® as both a palliative
and therapeutic treatment for the virus in the US and the DR, with positive
data from preclinical studies suggesting its effectiveness. Given that
Escozine® has received product registration as a natural alternative medicine
in Dominican and been a part of these clinical studies, physicians at the
clinic provided doses to certain vaccine recipients and observed this
reduction in side effects.
Escozine®, which is comprised of scorpion peptides that have been polarized by
the Company’s proprietary process, is Medolife’s lead drug candidate. The
Company recently announced that it has received a detailed response from the
US Food and Drug Administration (FDA) on its Pre-Investigational New Drug
(Pre-IND) submission on Escozine® as both a potential palliative and
therapeutic drug for the COVID-19 virus. In the response, the FDA acknowledged
the Company’s clinical trial that took place in the DR as a proof-of-concept
study and provided detailed guidelines for next steps in its approval process.
The Company is in the process of outlining an additional DNA toxicology study
as well as a formal clinical Pharmacokinetic (PK) study that it hopes to
launch in short order.
About Medolife Rx
Medolife Rx, Inc. is a global biotechnology company with operations in
clinical research, manufacturing, and consumer products. Medolife Rx was
created through the merger of Medolife, a private company founded by Dr.
Arthur Mikaelian who pioneered the unlaying polarization technology that makes
the Company’s portfolio of pharmaceutical and nutraceutical products so
effective, and Quanta, Inc., a direct-to-consumer wellness product portfolio
company. The Company’s lead clinical development programs include Escozine®, a
proprietary formulation consisting of small molecule peptides derived from
Rhopalurus princeps scorpions, which is amplified by the Company’s
polarization technology and is being researched as a treatment of various
indications, including COVID-19 and cancer. The Company has completed
preclinical safety and efficacy research on Escozine® and is pursuing product
registration and drug approval in various countries, including the United
States and throughout Latin America.
Through its subsidiary QuantRx, Medolife manufactures and distributes consumer
wellness products in high-impact consumer areas such as pain relief, beauty,
and general wellness. QuantRx products are designed using Dr. Mikaelian’s
polarization technology, which applies advances in quantum biology to increase
the potency of active ingredients. Ultimately, Quanta's mission is to deliver
better, more effective ingredients to elevate product efficacy, reduce waste,
and facilitate healthier, more sustainable consumption.
Beyond its own clinical and consumer applications, the polarization technology
used by Medolife and its subsidiaries has many potential applications. From
potentiating bio-ingredients, to producing more-effective carbon-trapping
plants, to transformative anti-aging solutions, Medolife has the opportunity
to upend how commercial and pharmaceutical products are made and increase
their benefits, while decreasing their chemical concentration.
Forward-Looking Statements
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act
of 1995: This release contains statements that are forward-looking in nature
which express the beliefs and expectations of management including statements
regarding the Company's expected results of operations or liquidity;
statements concerning projections, predictions, expectations, estimates or
forecasts as to our business, financial and operational results and future
economic performance; and statements of management's goals and objectives and
other similar expressions concerning matters that are not historical facts. In
some cases, you can identify forward-looking statements by terminology such as
"anticipate," "estimate," "plan," "project," "continuing," "ongoing,"
"expect," "we believe," "we intend," "may," "will," "should," "could," and
similar expressions. Such statements are based on current plans, estimates and
expectations and involve a number of known and unknown risks, uncertainties
and other factors that could cause the Company's future results, performance
or achievements to differ significantly from the results, performance or
achievements expressed or implied by such forward-looking statements. These
factors and additional information are discussed in the Company's filings with
the Securities and Exchange Commission and statements in this release should
be evaluated in light of these important factors. Although we believe that
these statements are based upon reasonable assumptions, we cannot guarantee
future results. Forward-looking statements speak only as of the date on which
they are made, and the Company undertakes no obligation to update publicly or
revise any forward-looking statement, whether as a result of new information,
future developments or otherwise.
Contacts:
medolife@cmwmedia.com
My position is Long hold $$$ QNTA
IMO the company has a lot going fit it - here’s the DD copy paste for you to look at … the stock has been heavily manipulated these last few months… IMO they won’t be able to hold it back much longer, if at all …
Tick tock …. I’m in it for the long haul
GLTA MedolifeRx AELIA escozine QNTA
Quanta, Inc. (QNTA) Basic Due Diligence Package
[Suppressed Image]
Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian who has completed all research and the development process and has attained the legal registration to commercialize the Blue Scorpion venom based product under the name of Escozine.
https://medolife.com/
Escozine™ was originally developed and commercialized by Medolife, Corp. in 2007. Until 2007, this natural medicine has only been available in Cuba, where it is known as Escozul. Medolife currently holds the exclusive patent license, (United States patent # 8,097,284 B2) of the bioactive peptide and polarization technology used to make the Polarized Dilute Blue Scorpion Venom. Escozine™, is registered and certified for oncological treatment by the Minister of Health in the Dominican Republic. Escozine™ is currently distributed in six countries (Dominican Republic, Vietnam, Russia, Belarus, Nigeria and Kazakhstan).
Escozine has been used for years to treat humans with cancer in many countries and its positive results are backed by numerous scientific research, pre-clinical and clinical observations that confirm its safety and efficacy.
Medolife has been successfully marketing its Escozine products through direct sales in 40 countries. Medolife has invested over $10 million in R&D in Escozine (for humans) over 10 years and amassed substantial scientific documentation, worldwide of its effectiveness.
CLOSER TO FDA APPROVAL, for its Pre-Investigational New Drug (PIND #150335) filing on its lead drug candidate Escozine® as a COVID-19 therapeutic. May 13th marks 30 days since the application.
[Suppressed Image]
Escozine® is a patented anti-cancer nutraceutical derived from the Caribbean blue scorpion that shows an 89.5% success rate in clinical trials
[Suppressed Image]
ESCOZINE-HPOur latest product combines the power of Escozine with renown homeopathic ingredients Bryonia albaand Echinacea purpurea for cancer patients undergoing or recovering from chemotherapy. National Drug Code 70891-201-01
[Suppressed Image]
AMAZING VIDEO: MEDOLIFE PRESENTS THE PRODUCE OF ESCOZINE
//www.youtube.com/watch?v=jZjs9e5Jfj4
Medolife has its own independent source of Blue Scorpion venom in the Dominican Republic and has established the world’s first Scorpion reservation which is 50,000 square meters and can produce millions of doses to meet global demand.
//www.youtube.com/watch?v=hHWTOkfKNnM
Escozine™ serum has demonstrated promising results in human preclinical studies in 2012 at UCSD Moores Cancer Center, as well as human clinical observations; results from UCSD also showed that Escozine had significant synergy with traditional chemotherapy agents cyclophosphamide, Fludarabine, Etoposide and others. Many Escozine users have combined the product with chemotherapy, radiation, hormone therapy and other conventional treatments with positive results. In 2007, Medolife collaborated with Atheris Laboratory in Switzerland, one of the world leaders in the study and analysis of crude venoms, to confirm that the venom of Rhopalurus Junceus from Cuba and Rhopalurus Princeps from Dominican Republic both share similar properties and have similar mechanisms of action in cancer cells.
In 2012, UCSD (University of California San Diego, Moores Cancer Center, together with Medolife Corp.) conducted research using polarized dilute Blue Scorpion venom utilizing the Mikaelian patented process # US 8097284 B2. The results demonstrated up to 95% apoptotic (programmed cell death) effect in a variety of cancer cell lines incubated for 48 hours, and showed a binding preference to cancer cells only while not affecting normal cells. Additionally, the study showed a synergistic effect with traditional chemotherapy treatments. Research anticipates that PetLife’s Escozine for Pets™ will also extend the life of pets suffering from cancer and improve their quality of life.
ABC NEWS! Old but well worth to view.
//www.youtube.com/watch?v=ZYGeiBa18OA
Medolife said Escozine is an effective cancer treatment because a peptide in the venom called chlorotoxin -- the same chemical that paralyzes prey -- also happens to target and kill cancer cells.
https://abcnews.go.com/Health/scorpion-venom-cure-ails/story?id=20755012
Very Interesting:))How Scorpion Venom Is Helping Doctors Treat Cancer. When injected into the body, Tumor Paint lights up cancers. The drug could lead to a new class of therapeutics
https://www.smithsonianmag.com/innovation/how-scorpion-venom-is-helping-doctors-treat-cancer-180960815/
Amazing! Targeting brain cancer with scorpion venom
//www.youtube.com/watch?v=R5C5Ui0O9PE
Quanta Inc (OTCMKTS:QNTA) Groundbreaking Results In Escozine® Testing
https://drpgazette.com/2021/04/09/quanta-inc-otcmktsqnta-groundbreaking-results-in-escozine-testing/
I read this news again and thinking this is much bigger than I thought...
Quote:
The registration was renewed after the Company provided study data on the efficacy of Escozine® in assisting cancer treatments of various kinds including common types of cancer such as breast, prostate, lung, and some uncommon forms of cancer such as bladder and ovarian. The registration allows for Escozine® to be marketed as a bioactive alternative cancer medicine across the DR and most other countries in Latin America, where the burden of cancer and mortality rates are among the highest in the world.
The Company also plans to negotiate with the government in the DR for the purchase of Escozine® for use as a treatment for COVID-19.
https://www.globenewswire.com/news-release/2021/05/04/2222245/0/en/Medolife-Rx-Announces-Historic-Product-Registration-in-Dominican-Republic-Enabling-Escozine-to-Be-Sold-Throughout-Latin-America-as-Natural-Alternative-Cancer-Medicine.html
Medolife Rx Receives Significant Purchase Order of Immunapen. The purchase order for 1,400 Immunapen™ Originals came from a pharmaceutical wholesaler based in the Republic of Armenia who will distribute the products throughout the region. This is the first purchase order from the wholesaler and the Company hopes that it will be the beginning of a strong relationship.
The Company also has developed Immunapen™ Anti-Anxiety, Immunapen™ Sleep, and Immunapen™ Energy & Focus.
https://ir.quantrx.com/news-events/press-releases/detail/57/medolife-rx-receives-significant-purchase-order-of
Quanta PRODUCTS are being Sold on Amazon
https://www.amazon.com/s?k=quanta+cream&crid=2PIYH1N70PCN2&sprefix=quanta+%2Caps%2C197&ref=nb_sb_ss_ts-doa-p_9_7
QUANTA PRODUCTS:
https://quantrx.com/shop/
QUANTA VIDEO:
https://quantrx.com/quanta-videos/
Management Team:
Arthur G. Mikaelian.
[Suppressed Image]
For the past 20 years Dr. Mikaelian has been independently actively studying stress hormones (cortisol, epinephrine), master gene (ATF3) and their indirect influences on cancer cell activity and tumor progression. His initial findings quickly led him to the innovative creation of a new generation of nutraceuticals and pharmaceutical drugs, as well as expanding his interests in cancer and oncology.
One of Dr. Mikaelian’s greatest scientific contributions and ground-breaking inventions is his Polarization technology which targets key elements in the main ingredients of medications, leading to the intensification of potency of liquid or solid compounds, which substantially increases their therapeutic effectiveness. Dr. Mikaelian’s polarization technology has been awarded U.S. Patent 8,097,284 B2 as it pertains to Polarized Scorpion Venom solution and the method for making it.
Dr. Mikaelian’s technical education began at the 2nd Medical Institute of Moscow and continued at the Vernadsky University of Biosphere Knowledge in Moscow, where he earned his doctorate in Biological Psychology; he then went on to complete his post-doctorate work at Vernadsky University. He also earned an MBA from the University of Bologna, located in Italy.
[Suppressed Image]
Prof. Khalid Z Matalka
Dean of Faculty of Health Sciences
Professor of Immunology
American University of Madaba
Jordan
Tel: 617-816-5175
Full_biography:
https://scholars.direct/editor-Full_biography.php?jid=immunology&eid=LB93695207
For the past 20 years Dr. Mikaelian has been independently actively studying stress hormones (cortisol, epinephrine), master gene (ATF3) and their indirect influences on cancer cell activity and tumor progression. His initial findings quickly led him to the innovative creation of a new generation of nutraceuticals and pharmaceutical drugs, as well as expanding his interests in cancer and oncology.
One of Dr. Mikaelian’s greatest scientific contributions and ground-breaking inventions is his Polarization technology which targets key elements in the main ingredients of medications, leading to the intensification of potency of liquid or solid compounds, which substantially increases their therapeutic effectiveness. Dr. Mikaelian’s polarization technology has been awarded U.S. Patent 8,097,284 B2 as it pertains to Polarized Scorpion Venom solution and the method for making it.
Dr. Mikaelian’s technical education began at the 2nd Medical Institute of Moscow and continued at the Vernadsky University of Biosphere Knowledge in Moscow, where he earned his doctorate in Biological Psychology; he then went on to complete his post-doctorate work at Vernadsky University. He also earned an MBA from the University of Bologna, located in Italy.
More on Magagement team view link below:
https://ir.quantrx.com/company-information/management-team
Share Structure:
Market Cap Market Cap
9,493,409 05/11/2021
Authorized Shares
500,000,000 04/09/2021
Outstanding Shares 102,079,666 04/09/2021
Restricted 24,436,248 04/09/2021
Unrestricted 77,643,418 04/09/2021
[Suppressed Image]
Never mind if day traders are familiar with QNTA, they’ll chase it later … many doctors / medical / science communities are “as of Yet” unfamiliar …. (Yet is the operative word … the company purposely did research under the radar, entering the muscle rub category as a proof of concept move .. now they are ready to tell the world of the huge benefit of the polarization technology which QNTA has the patent for)
>>> Once the right entities get wind of the science, data, research, proof of concept, etc … it’ll be great …
IMO anyways the potential is huge!
I agree regarding those manipulating this stock, it’s an attempt to rattle long holders of their shares …
Also, hugely worth noting, AELIA products are just getting on shelves - ONCE people use, appreciate their fantastic efficacy, they will reorder and subsequently share their positive findings with friends, family and their doctors/ chiropractors / therapists etc ….
….it’ll be like the hair commercial “and they tell two friends and so on” …
I’m hanging tight :)
Sure being red is unfun.
But I’m truly excited for future prospects
Which, IMO, the future looks bright QNTA $$
QNTA … long investment
MedolifeRx AELIA escozine QNTA
real company, with real products, real science, real data, and real patents …
This one isn’t a “play” on hype - it’s an investment in science, innovation, patented technology and product.
If your day is consumed with chasing hype on day trades, that’s great … however for those who recognize and have invested in the 16 years of research and development of escozine and the polarization technology / patent … I’d say it’s just a different approach of allocation of funds and investment strategy….
GLTA long here QNTA $$$
IMO Lots to be excited about here $$$
“Other Latin countries” Qnta $$$$
escozine Imunapen MedolifeRx AELIA
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
“the Vice President also expressed a strong desire to solidify an agreement to introduce the benefits and effectiveness of Escozine® as a COVID-19 therapy to other countries. Finally, the VP shared that she will look to make plans to visit the Company’s first-of-its-kind scorpion reservation and manufacturing facility.
“This creates an opportunity for Medolife to demonstrate Escozine’s effectiveness in the country as a therapeutic and palliative medicine,” said Medolife CEO Dr. Arthur Mikaelian. “Through our study on Escozine®, we were able to show that it diminishes some of the side-effects of vaccines. This creates more confidence by the general population and further aids governments in implementation of vaccine programs. Beyond the opportunity for us to help the population of the DR, an approval of this kind will open the door to further negotiations for distribution in other Latin American countries. Overall, the outcome of the meeting was very positive, and we look forward to working closer with the Vice President and government of the DR.”
https://ir.quantrx.com/news-events/press-releases/detail/93/medolife-rx-announces-that-the-government-of-the-dominican?fbclid=IwAR2hQ3jDLw76mcb5nKjdkHvWebTH4f2pzZdD_OwyxiY1jXaPSu9-QtZEUQI
Great news!!! Qnta $ : “Beyond the distribution of Escozine® throughout the DR, the Vice President also expressed a strong desire to solidify an agreement to introduce the benefits and effectiveness of Escozine® as a COVID-19 therapy to other countries. Finally, the VP shared that she will look to make plans to visit the Company’s first-of-its-kind scorpion reservation and manufacturing facility.
“This creates an opportunity for Medolife to demonstrate Escozine’s effectiveness in the country as a therapeutic and palliative medicine,” said Medolife CEO Dr. Arthur Mikaelian. “Through our study on Escozine®, we were able to show that it diminishes some of the side-effects of vaccines. This creates more confidence by the general population and further aids governments in implementation of vaccine programs. Beyond the opportunity for us to help the population of the DR, an approval of this kind will open the door to further negotiations for distribution in other Latin American countries. Overall, the outcome of the meeting was very positive, and we look forward to working closer with the Vice President and government of the DR.”
Medolife’s CEO also shared details of some of the other products that Company produces such as its line of Immunapens, which are formulated into four effects-based products: energy and focus, stress relief, sleep aid, and general immune support. The government official shared additional enthusiasm for those products and her interest in their distribution as well. Mikaelian also discussed how the Company could assist in the financial applications of such a large Escozine® distribution through philanthropic initiatives that positively support larger health-related needs of the government healthcare system.”
https://ir.quantrx.com/news-events/press-releases/detail/93/medolife-rx-announces-that-the-government-of-the-dominican
“Looks to expand into other APIs”
IMO This has huge potential QNTA
QNTA patented polarization technology $
{{The active ingredient in a pharmaceutical drug is called an active pharmaceutical ingredient (API). An example of an API is the acetaminophen contained in a pain relief tablet.}}
8:43a ET 10/12/2021 - Globe Newswire
Medolife Rx Reports 257% Increase in Efficacy of Ibuprofen Through Proprietary Polarization Method, Looks to Expand Into Other APIs
Mentioned: QNTA
via NewMediaWire - Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today results from a study on its patented polarization methodology that compared the effectiveness of generic ibuprofen, a well-known pain relief drug that works by lowering inflammation by inhibiting the cyclooxygenase-2 (COX-2) enzyme's activity in the body, versus polarized ibuprofen in inhibition of COX-2 activity in humans. The results showed that polarized ibuprofen was 257% more effective in inhibiting COX-2, which is expressed in inflammation and pain in humans. The result further solidifies the potential applications of polarization on the healthcare industry as a whole, whereas the therapeutic efficacy of active pharmaceutical ingredients (APIs) can be increased through the process, and dosage can be decreased, resulting in fewer side effects and potential damage to the liver.
The study took place at the Pasadena Bio Collaborative Incubator, using a COX-2 assay from Cayman Chemical Company. The assay provided a fluorescent base for screening human recombinant COX-2 and the study was performed with black flat bottom 96-well plates with results measured on Spectramax ID3 multi-mode microplate readers. The experiment looked at COX-2 inhibition when three different forms of ibuprofen were introduced: one non-polarized, one negative polarized, and one polarized. The results, as shown in Figure 1.1, showed an increase of COX-2 inhibition in the polarized sample when compared to the non-polarized sample, where the inhibition was 257.67% higher than the non-polarized sample of ibuprofen.
"Beyond everything else we are doing, at the core of our company's value remains the potential for the use of the polarization technology across the healthcare spectrum," said Medolife CEO Dr. Arthur Mikaelian. "Through this test we validated yet again how well polarization works in increasing the efficacy of APIs. A 257% increase in efficacy is truly a scientific breakthrough for the medical community. While ibuprofen is seemingly harmless on the body at low doses, it has led to stomach bleeding and other serious side effects with continued use. This is the case with many major pharmaceutical drugs. Some of the world's most effective medicines can cause significant side effects and damage to the internal body. If we were able to introduce polarization to some of these, we could decrease the dose necessary to achieve the desired effect, in turn reducing this potential damage and associated side effects. This could apply to drugs such as chemotherapy, which is well-known for its adverse side effects, yet is used in a large percentage of cancer treatments. We are looking to partner with large pharmaceutical companies such as AstraZeneca and Pfizer, among others who produce chemotherapy drugs, in order to introduce them to polarization. Through our process we could increase the efficacy of chemo while reducing the dose required, alleviating the side effects of that drug for thousands if not millions of patients. The applications for this technology are truly endless and we've proven once again that it works with almost any API."
While the Company continues to pursue regulatory approval on its pharmaceutical product Escozine(R), it is actively seeking additional studies and collaborations with major pharmaceutical companies to explore how polarization could be used to increase the efficacy of some of the world's leading drugs.
About Medolife Rx
Medolife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing, and consumer products. Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian who pioneered the unlaying polarization technology that makes the Company's portfolio of pharmaceutical and nutraceutical products so effective, and Quanta, Inc., a direct-to-consumer wellness product portfolio company. The Company's lead clinical development programs include Escozine(R), a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions which is amplified by the Company's polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. The Company has completed preclinical safety and efficacy research on Escozine(R) and is pursuing product registration and drug approval in various countries, including the United States and throughout Latin America.
Through its subsidiary QuantRx, Medolife manufactures and distributes consumer wellness and nutraceutical products in high-impact consumer areas such as pain relief, beauty, and general wellness. QuantRx products are designed using Dr. Mikaelian's polarization technology which applies advances in quantum biology to increase the potency of active ingredients. Currently, QuantRx supports product formulations in pain management, anti-inflammation, skincare, agriculture, nutritional supplements, and plant-based consumables. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste, and facilitate healthier, more sustainable consumption.
Beyond its own clinical and consumer applications, the polarization technology used by Medolife and its subsidiaries has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Medolife has the opportunity to upend how commercial and pharmaceutical products are made and increase their benefits, while decreasing their chemical concentration.
Forward-Looking Statements
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regarding the Company's expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management's goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "will," "should," "could," and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Contacts:
ir@medoliferx.com
https://ml.globenewswire.com/media/dbe8fad7-b222-45ce-92ef-446b52583d6e/small/quanta-logo-png.png
https://ml.globenewswire.com/media/dbe8fad7-b222-45ce-92ef-446b52583d6e/small/quanta-logo-png.png
comtex tracking
COMTEX_395019357/2010/2021-10-12T08:43:38
The thing is, big pharma could charge the same money too … if a cup of espresso often costs more than a plain cup of coffee. … then it wouldn’t be weird to buy a smaller sized “Advil” for example that’s more potent and pay more …
Hopefully that’s how the companies see it too … in an ideal world it’d be great to see final customers cost go down with the use of smaller dose of medicine… in the mean time big pharma likes their big bank accounts… they’d be wise to jump on this and market it to their benefit $$$
Ugh, “shorting” it’s just not right IMO …
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
“'Short selling should be illegal'
https://markets.businessinsider.com/news/stocks/tesla-spacex-ceo-elon-musk-short-selling-should-be-illegal-2019-12
Qnta $ Press release: {“Beyond everything else we are doing, at the core of our company’s value remains the potential for the use of the polarization technology across the healthcare spectrum,” said Medolife CEO Dr. Arthur Mikaelian. “Through this test we validated yet again how well polarization works in increasing the efficacy of APIs. }
https://ir.quantrx.com/news-events/press-releases/detail/92/medolife-rx-reports-257-increase-in-efficacy-of-ibuprofen
“polarization methodology is patented and efficacious” QNTA follow the science $
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
“Science is about constant improvement, and we achieved a very tangible example of that in this case,” Dr. Mikaelian said. “While our polarization methodology is patented and efficacious, we are working on a new scientific approach, and that provides us the opportunity to identify inefficiencies and make changes to improve them. In this case, we took a very successful process and made it even better. This further illustrates to me that we have so much more room for scientific breakthroughs in the work we are doing, even beyond our proven approach to polarization.”
https://www.globenewswire.com/en/news-release/2021/05/06/2224499/0/en/Medolife-Rx-Implements-Proprietary-Electro-Solution-Further-Increasing-Efficacy-of-Polarization-Technology.html
Research .. you’ll see lots to be said about this as a long hold investment … like many things I’m life they’ve had some delays .. which have all been explained… listen to the conference calls and read all their announcements… IMO the stock is good
Over 16 years of research … so, the way I see it, a couple months of delay after 16 years of research and strategic mergers culminating together is negligible.. especially if one is invested in the company … medicinal items, if taken seriously by the globe, are held to high standards of testing & substantiated data…. Some are frustrated they didn’t make money over night here … IMO this stock is an investment not a flip .. I’m long and holding and impressed by the diligent research and steps made to get them to the position they are in now …
- - - - - - - - QNTA - - - - - - - -
“The founder of Medolife, Dr. Arthur Grant Mikaelian, started his independent investigation in 2004 related to the Caribbean Blue Scorpion. Scientific data, which was available at the time, made him believe that the scorpion venom had potential therapeutic values. He was sure it could be a valuable organic compound when combined with his polarization technology.”
- - - -
Worth noting … research and development of anything “pharmaceutical” related takes time …
- - - - -
“Upon product registration in the DR, Medolife estimates demand for Escozine® could be upwards of one million doses in the first quarter after registration. The Company is actively scaling up cultivation of the peptide in order to meet this demand, as well as planning an additional expansion to the reservation in the form of a medical lab facility on the premises, which would decrease logistical costs in the Escozine® production process. Beyond its pending product registration in the DR, data on Escozine® has been submitted to the US Food and Drug Administration (FDA) through the Investigational New Drug regulatory pathway, which, if approved, would make Escozine® available to patients in the US in a matter of months.
“With a gallon of scorpion venom costing upwards of $39 million, expanding our own cultivation reservation in order to meet our internal demand for the peptides used in Escozine only made further sense,” said Medolife CEO Dr. Arthur Mikaelian. “We have one of the largest scorpion reservations in the world and this expansion only further solidifies that position. As we await our pending regulatory approvals, which we expect in short order starting within the DR, we must prepare to meet the immediate demand the approvals will render by increasing our scorpion cultivation efforts. While we plan to focus first on the Rhopalurus princeps, which is one of several types of Blue Scorpions, the expansion will also allow us to add other scorpions such as Rhopalurus abudi, whose venom has seen promising results in treating various cancers. Our next step of adding a lab facility to the location is imminent, and we will be able to fully integrate our supply chain of Escozine® and further position Medolife as an integrated global pharmaceutical and nutraceutical company.”
- - - - - -
GLTA :~$) paytience .. IMO will pay
https://medolife.com/history/
https://www.globenewswire.com/en/news-release/2021/03/30/2201650/0/en/Medolife-Rx-Furthers-Expansion-of-Scorpion-Reservation-Prepares-for-Mass-Production-of-Escozine-Required-Upon-Product-Registration.html
15 years of research …
https://www.stocktitan.net/news/QNTA/medolife-rx-initiates-comparative-study-of-its-flagship-cbd-based-mnck3kl4aeht.html
“We know that polarized CBD, along with polarized Ibuprofen and Escozine®, are effective in inhibiting the COX-2 enzyme, as shown by the previous studies we have completed,” said Medolife CEO Dr. Arthur Mikaelian. “While we hope to further prove the hypothesis in future studies, the purpose of this study is to show the variance between COX-2 inhibition in standard CBD products that are currently on the market, which are non-polarized, when compared to our muscle rub product, which includes polarized CBD. We are beyond confident that the variance will be vast and that yet again we will prove we have one of the most effective products in the pain relief category available today.”
Good company.. Just ran in to some of the same woes as many during the covid shipping issues … this caused a great delay in them being able to push out their products… as for the ticker change and fda we are unfortunately at the mercy of government type workers timelines
I’m long. And holding qnta $
I’m Holding!! :)
I’ve worked with artists / engineers / inventor types before … often those with brilliant ideas are not the same ones who in turn promote the idea $$$ .. patience here is what I have … IMO This company is making smart pragmatic collaborations … new products have only just recently landed on the shelves … the fda asked for additional data because of new requirements - which qnta subsequently obliged and shared with the investors how and with whom they are getting these new required data sets accomplished…. New stock ticker will happen soon, the scorpion ranch expansion progress is getting praise from the DR government … escozine gave great relief to medical staff and patients alike in the DR to the unvaccinated and vaccinated alike saw positive results from escozine use ..
Noteworthy : qnta has patented polarization technology that the patent alone is valuable $$
I’m holding long here and continue to be optimistic. IMO qnta is like the little engine that could … and IMO it will be the little engine that does $$ ;) $$
If true they are thinking to not call a “vaccine” is Good to hear, as it never was a vaccine by definition… oddly though, and I’m not kidding, recently the definition of vaccine online was altered (literally altered)… sadly I feel there is a bizarre consensus that if you simply change a definition of a word the facts change with it …the online definition for fascist was changed as well … again, changing words doesn’t change a spade from being a spade.
I wish the world (the US) would look away from “only” big pharma and put their money where their mouths are … ie “look at science” (escozine as science data to be specific). all this yelling about “following the science” and yet … many seem to almost shun the notion of therapeutics.. meanwhile therapeutics are showing great things where they are being used. QNTA has the data to support its escozine efficacy as a therapeutic… covid is clearly NOT a one size fits all thing … the extremes in how different it affects one person versus the other is bizarre …
- on a side note, I know 2 people who used with great success fda approved cancer treating therapeutics to battle lung cancer .. both women improved dramatically- thus the fda knows there is merit in therapeutics…
Back to QNTA escozine, let’s hope they, the FDA, are satisfied with the data that was/ gets submitted by Medolife the fda subsequently requested this summer .. what we know; the govt of the DR has faith in QNTA as shown by their partnership with the Scorpion ranch expansion (if the data and research didn’t show promise they wouldn’t expand in the first place) ..
- sadly, covid 19 delta variant is likely only the beginning of things we will see in our lifetime as like the flu, covid is evolving / mutating .. we can’t be getting booster shots for infinitum … there has to be other ways … cue and enter escozine ;~)
In the meantime regardless of “vaccination status” wash hands regularly etc … I have friends both vaccinated and non-vaccinated who have recently dealt with / suffered with covid …
GLTA I’m optimistic and long here $
Just biding our time … I’m 100% long still and holding my shares with a tight grip
They are pushing out the product line as they said they were .. and as far as ticker and fda we are on those agencies time lines now … in the mean time - I’m ordering some products today :)
And in addition to some for me I’m ordering as a gift for someone… if we all did that we’d help generate sales for one, secondly it’s like the old shampoo comercial “and they told two friends and they told two friends “ etc …
It’s my understanding from another investor who used the imunapen it was GREAT! And another used the muscle rub says the same - great! Soooo if you know anyone with aches pains tension stress?
Break out your wallets and make a purchase!!! This company has a lot great products and technology… as share holders we can help spread the word best if we are utilizing there products
Anyways … that’s my 2 cents for the day..
Any one new to the board, research this company and you’ll find a solid business plan - delay in AELIA packaging because of covid global shipping slow downs BUT now they have the product packed and ready for orders :)
Happy October everyone - let’s hope for no tricks this Halloween ONLY treats ;)
GLTA $$ QNTA
https://medoliferx.com/shop/drops/escozine-immunapen-plus-anti-anxiety/
All Medolife RX Immunapens contain a patented polarized solution of Rhopalurus princeps scorpion venom. Venom therapies and treatments have been used for centuries by indigenous people and now have been widely adopted by the medical community as treatments to aid in reducing inflammation, pain and modulating immune response.
Currently, animal venom components are being used as valuable and powerful pharmacological tools. Venom derived-grugs have been producted bt the pharmaceutical industry since the 1970's. Current pharmaceuticals utilize snake, scorpion. snail, and sea anemone venom components. These highly regarded medicines are used to treat cancer, high blood pressure, auto immune disease, MS and HIV.
Hilarious !!!
… and probably they will … lol !!!
While we wait p a t i e n t l y for new news
… always good to good over old news ;)
They’ve (qnta MedolifeRx AELIA) made great strategically sound moves in regards to mergers etc …
Link pasted below the excerpt;
(Re the qnta Merger…) “ to allow for the expansion of Medolife's Polarization Technology platform to anti-viral/immunity-boosting therapies. Medolife Rx's focus is on R&D and production of pharmaceutical-grade products, as well as clinical evidence-based nutraceuticals, utilizing patented Polarization Technology. Medolife Rx's technology will impact various industries with projections in multibillion dollar gains. “
https://markets.businessinsider.com/news/stocks/quanta-announces-acquisition-of-51-of-medolife-rx-1029913574
Here’s the article pasted in it’s entirety below - I’m not sure why the link didn’t work…
It’s amazing how effective escozine Is with not only covid but in conjunction with the vaccine as well … add in all the AELIA products and the company’s
Business
Quanta, Inc.: Medolife Rx Clinical Observations Demonstrates Effectiveness of Escozine in Complementary Use with COVID-19
July 8, 2021, 8:30 AM EDT
BURBANK, Calif., July 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife
Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D,
manufacturing, and consumer product distribution, which is a majority owned
subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today new clinical
observations made on its lead drug candidate Escozine®.
Physicians observed that patients who originally had strong adverse reactions
to COVID-19 vaccines and who were given Escozine®, experienced significantly
lessened side effects. Typical vaccine side effects are similar to symptoms of
the actual COVID-19 virus, including body cough, aches, fatigue and fever,
among others.
These observations have led the Company to move forward with pursuing an
additional pilot study on the drug, looking to prove its effectiveness in
decreasing side effects of vaccinations for COVID-19. Management plans to meet
with the Ministry of Health and the office of the President of the DR to
present the observations and seek further guidance on next steps for approval
as a complimentary product for vaccine recipients.
“It only makes sense that Escozine® would be effective in mitigating side
effects of COVID-19 vaccines as it has been proven to be effective in treating
or diminishing the symptoms of the COVID-19 virus itself,” said Medolife CEO
Dr. Arthur Mikaelian. “Specifically in the DR, and in many places around the
world, vaccine hesitancy is becoming more common for a multitude of reasons,
including the side effects associated with them. While the idea of pursuing
Escozine® as a complementary product to COVID-19 vaccines was not originally
included in our study parameters, we plan to quickly initiate a pilot study in
order to prove its potential effectiveness as such. If we are able to do so,
Escozine® could have global applications as a complementary medicine,
decreasing the severity of side effects of COVID-19 vaccines, and hopefully,
decreasing vaccine hesitancy in patients with a high side effect risk rate.”
The Company is currently pursuing approval of Escozine® as both a palliative
and therapeutic treatment for the virus in the US and the DR, with positive
data from preclinical studies suggesting its effectiveness. Given that
Escozine® has received product registration as a natural alternative medicine
in Dominican and been a part of these clinical studies, physicians at the
clinic provided doses to certain vaccine recipients and observed this
reduction in side effects.
Escozine®, which is comprised of scorpion peptides that have been polarized by
the Company’s proprietary process, is Medolife’s lead drug candidate. The
Company recently announced that it has received a detailed response from the
US Food and Drug Administration (FDA) on its Pre-Investigational New Drug
(Pre-IND) submission on Escozine® as both a potential palliative and
therapeutic drug for the COVID-19 virus. In the response, the FDA acknowledged
the Company’s clinical trial that took place in the DR as a proof-of-concept
study and provided detailed guidelines for next steps in its approval process.
The Company is in the process of outlining an additional DNA toxicology study
as well as a formal clinical Pharmacokinetic (PK) study that it hopes to
launch in short order.
About Medolife Rx
Medolife Rx, Inc. is a global biotechnology company with operations in
clinical research, manufacturing, and consumer products. Medolife Rx was
created through the merger of Medolife, a private company founded by Dr.
Arthur Mikaelian who pioneered the unlaying polarization technology that makes
the Company’s portfolio of pharmaceutical and nutraceutical products so
effective, and Quanta, Inc., a direct-to-consumer wellness product portfolio
company. The Company’s lead clinical development programs include Escozine®, a
proprietary formulation consisting of small molecule peptides derived from
Rhopalurus princeps scorpions, which is amplified by the Company’s
polarization technology and is being researched as a treatment of various
indications, including COVID-19 and cancer. The Company has completed
preclinical safety and efficacy research on Escozine® and is pursuing product
registration and drug approval in various countries, including the United
States and throughout Latin America.
Through its subsidiary QuantRx, Medolife manufactures and distributes consumer
wellness products in high-impact consumer areas such as pain relief, beauty,
and general wellness. QuantRx products are designed using Dr. Mikaelian’s
polarization technology, which applies advances in quantum biology to increase
the potency of active ingredients. Ultimately, Quanta's mission is to deliver
better, more effective ingredients to elevate product efficacy, reduce waste,
and facilitate healthier, more sustainable consumption.
Beyond its own clinical and consumer applications, the polarization technology
used by Medolife and its subsidiaries has many potential applications. From
potentiating bio-ingredients, to producing more-effective carbon-trapping
plants, to transformative anti-aging solutions, Medolife has the opportunity
to upend how commercial and pharmaceutical products are made and increase
their benefits, while decreasing their chemical concentration.
Forward-Looking Statements
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act
of 1995: This release contains statements that are forward-looking in nature
which express the beliefs and expectations of management including statements
regarding the Company's expected results of operations or liquidity;
statements concerning projections, predictions, expectations, estimates or
forecasts as to our business, financial and operational results and future
economic performance; and statements of management's goals and objectives and
other similar expressions concerning matters that are not historical facts. In
some cases, you can identify forward-looking statements by terminology such as
"anticipate," "estimate," "plan," "project," "continuing," "ongoing,"
"expect," "we believe," "we intend," "may," "will," "should," "could," and
similar expressions. Such statements are based on current plans, estimates and
expectations and involve a number of known and unknown risks, uncertainties
and other factors that could cause the Company's future results, performance
or achievements to differ significantly from the results, performance or
achievements expressed or implied by such forward-looking statements. These
factors and additional information are discussed in the Company's filings with
the Securities and Exchange Commission and statements in this release should
be evaluated in light of these important factors. Although we believe that
these statements are based upon reasonable assumptions, we cannot guarantee
future results. Forward-looking statements speak only as of the date on which
they are made, and the Company undertakes no obligation to update publicly or
revise any forward-looking statement, whether as a result of new information,
future developments or otherwise.
Contacts:
medolife@cmwmedia.com
https://www.bloomberg.com/press-releases/2021-07-08/quanta-inc-medolife-rx-clinical-observations-demonstrates-effectiveness-of-escozine-in-complementary-use-with-covid-19
Here’s the article pasted in it’s entirety below - I’m not sure why the link didn’t work…
It’s amazing how effective escozine Is with not only covid but in conjunction with the vaccine as well … add in all the AELIA products and the company’s
Business
Quanta, Inc.: Medolife Rx Clinical Observations Demonstrates Effectiveness of Escozine in Complementary Use with COVID-19
July 8, 2021, 8:30 AM EDT
BURBANK, Calif., July 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife
Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D,
manufacturing, and consumer product distribution, which is a majority owned
subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today new clinical
observations made on its lead drug candidate Escozine®.
Physicians observed that patients who originally had strong adverse reactions
to COVID-19 vaccines and who were given Escozine®, experienced significantly
lessened side effects. Typical vaccine side effects are similar to symptoms of
the actual COVID-19 virus, including body cough, aches, fatigue and fever,
among others.
These observations have led the Company to move forward with pursuing an
additional pilot study on the drug, looking to prove its effectiveness in
decreasing side effects of vaccinations for COVID-19. Management plans to meet
with the Ministry of Health and the office of the President of the DR to
present the observations and seek further guidance on next steps for approval
as a complimentary product for vaccine recipients.
“It only makes sense that Escozine® would be effective in mitigating side
effects of COVID-19 vaccines as it has been proven to be effective in treating
or diminishing the symptoms of the COVID-19 virus itself,” said Medolife CEO
Dr. Arthur Mikaelian. “Specifically in the DR, and in many places around the
world, vaccine hesitancy is becoming more common for a multitude of reasons,
including the side effects associated with them. While the idea of pursuing
Escozine® as a complementary product to COVID-19 vaccines was not originally
included in our study parameters, we plan to quickly initiate a pilot study in
order to prove its potential effectiveness as such. If we are able to do so,
Escozine® could have global applications as a complementary medicine,
decreasing the severity of side effects of COVID-19 vaccines, and hopefully,
decreasing vaccine hesitancy in patients with a high side effect risk rate.”
The Company is currently pursuing approval of Escozine® as both a palliative
and therapeutic treatment for the virus in the US and the DR, with positive
data from preclinical studies suggesting its effectiveness. Given that
Escozine® has received product registration as a natural alternative medicine
in Dominican and been a part of these clinical studies, physicians at the
clinic provided doses to certain vaccine recipients and observed this
reduction in side effects.
Escozine®, which is comprised of scorpion peptides that have been polarized by
the Company’s proprietary process, is Medolife’s lead drug candidate. The
Company recently announced that it has received a detailed response from the
US Food and Drug Administration (FDA) on its Pre-Investigational New Drug
(Pre-IND) submission on Escozine® as both a potential palliative and
therapeutic drug for the COVID-19 virus. In the response, the FDA acknowledged
the Company’s clinical trial that took place in the DR as a proof-of-concept
study and provided detailed guidelines for next steps in its approval process.
The Company is in the process of outlining an additional DNA toxicology study
as well as a formal clinical Pharmacokinetic (PK) study that it hopes to
launch in short order.
About Medolife Rx
Medolife Rx, Inc. is a global biotechnology company with operations in
clinical research, manufacturing, and consumer products. Medolife Rx was
created through the merger of Medolife, a private company founded by Dr.
Arthur Mikaelian who pioneered the unlaying polarization technology that makes
the Company’s portfolio of pharmaceutical and nutraceutical products so
effective, and Quanta, Inc., a direct-to-consumer wellness product portfolio
company. The Company’s lead clinical development programs include Escozine®, a
proprietary formulation consisting of small molecule peptides derived from
Rhopalurus princeps scorpions, which is amplified by the Company’s
polarization technology and is being researched as a treatment of various
indications, including COVID-19 and cancer. The Company has completed
preclinical safety and efficacy research on Escozine® and is pursuing product
registration and drug approval in various countries, including the United
States and throughout Latin America.
Through its subsidiary QuantRx, Medolife manufactures and distributes consumer
wellness products in high-impact consumer areas such as pain relief, beauty,
and general wellness. QuantRx products are designed using Dr. Mikaelian’s
polarization technology, which applies advances in quantum biology to increase
the potency of active ingredients. Ultimately, Quanta's mission is to deliver
better, more effective ingredients to elevate product efficacy, reduce waste,
and facilitate healthier, more sustainable consumption.
Beyond its own clinical and consumer applications, the polarization technology
used by Medolife and its subsidiaries has many potential applications. From
potentiating bio-ingredients, to producing more-effective carbon-trapping
plants, to transformative anti-aging solutions, Medolife has the opportunity
to upend how commercial and pharmaceutical products are made and increase
their benefits, while decreasing their chemical concentration.
Forward-Looking Statements
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act
of 1995: This release contains statements that are forward-looking in nature
which express the beliefs and expectations of management including statements
regarding the Company's expected results of operations or liquidity;
statements concerning projections, predictions, expectations, estimates or
forecasts as to our business, financial and operational results and future
economic performance; and statements of management's goals and objectives and
other similar expressions concerning matters that are not historical facts. In
some cases, you can identify forward-looking statements by terminology such as
"anticipate," "estimate," "plan," "project," "continuing," "ongoing,"
"expect," "we believe," "we intend," "may," "will," "should," "could," and
similar expressions. Such statements are based on current plans, estimates and
expectations and involve a number of known and unknown risks, uncertainties
and other factors that could cause the Company's future results, performance
or achievements to differ significantly from the results, performance or
achievements expressed or implied by such forward-looking statements. These
factors and additional information are discussed in the Company's filings with
the Securities and Exchange Commission and statements in this release should
be evaluated in light of these important factors. Although we believe that
these statements are based upon reasonable assumptions, we cannot guarantee
future results. Forward-looking statements speak only as of the date on which
they are made, and the Company undertakes no obligation to update publicly or
revise any forward-looking statement, whether as a result of new information,
future developments or otherwise.
Contacts:
medolife@cmwmedia.com
https://www.bloomberg.com/press-releases/2021-07-08/quanta-inc-medolife-rx-clinical-observations-demonstrates-effectiveness-of-escozine-in-complementary-use-with-covid-19
QNTA long / bullish… imo lots to be excited about with this stock … $$$
Great positive escozine data :
{“Physicians observed that patients who originally had strong adverse reactions
to COVID-19 vaccines and who were given Escozine®, experienced significantly
lessened side effects. Typical vaccine side effects are similar to symptoms of
the actual COVID-19 virus, including body cough, aches, fatigue and fever,
among others.
These observations have led the Company to move forward with pursuing an
additional pilot study on the drug, looking to prove its effectiveness in
decreasing side effects of vaccinations for COVID-19. Management plans to meet
with the Ministry of Health and the office of the President of the DR to
present the observations and seek further guidance on next steps for approval
as a complimentary product for vaccine recipients.
“It only makes sense that Escozine® would be effective in mitigating side
effects of COVID-19 vaccines as it has been proven to be effective in treating
or diminishing the symptoms of the COVID-19 virus itself,” said Medolife CEO
Dr. Arthur Mikaelian. “Specifically in the DR, and in many places around the
world, vaccine hesitancy is becoming more common for a multitude of reasons,
including the side effects associated with them. While the idea of pursuing
Escozine® as a complementary product to COVID-19 vaccines was not originally
included in our study parameters, we plan to quickly initiate a pilot study in
order to prove its potential effectiveness as such. If we are able to do so,
Escozine® could have global applications as a complementary medicine,
decreasing the severity of side effects of COVID-19 vaccines, and hopefully,
decreasing vaccine hesitancy in patients with a high side effect risk rate.”
The Company is currently pursuing approval of Escozine® as both a palliative
and therapeutic treatment for the virus in the US and the DR, with positive
data from preclinical studies suggesting its effectiveness. Given that
Escozine® has received product registration as a natural alternative medicine
in Dominican and been a part of these clinical studies, physicians at the
clinic provided doses to certain vaccine recipients and observed this
reduction in side effects.
Escozine®, which is comprised of scorpion peptides that have been polarized by
the Company’s proprietary process, is Medolife’s lead drug candidate. The
Company recently announced that it has received a detailed response from the
US Food and Drug Administration (FDA) on its Pre-Investigational New Drug
(Pre-IND) submission on Escozine® as both a potential palliative and
therapeutic drug for the COVID-19 virus. In the response, the FDA acknowledged
the Company’s clinical trial that took place in the DR as a proof-of-concept
study and provided detailed guidelines for next steps in its approval process.
The Company is in the process of outlining an additional DNA toxicology study
as well as a formal clinical Pharmacokinetic (PK) study that it hopes to
launch in short order.”}
https://www.bloomberg.com/press-releases/2021-07-08/quanta-inc-medolife-rx-clinical-observations-demonstrates-effectiveness-of-escozine-in-complementary-use-with-covid-19”}
Green is Good! QNTA
is a long hold for sure $$$ investment $$$
“QNTA: FILES FOR OTC-QB TIER CERTIFICATION !
https://www.otcmarkets.com/otcapi/company/financial-report/301794/content
Getting ready to move this puppy on up - FINRA NAME and SYMBOL CHANGE and QB-TIER hitting all at the same time will be a nice kicker to the share price :) “
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
- certainly Looking forward to this happening…. Hopefully soon … the company’s just as anxious as we are on iHub to see this occur!
In the mean time, nice to see the day looking green QNTA $
If we all put in orders … AND like / look at etc their social media it will help drive things … while I’m not so sure my family on fb bought any muscle rub (I didn’t ask) I did however post the Tony Hawk video awhile back … you never know whose attention WE investors might catch while posting plugs in our own social circles.. I’m not one to push products or a stock on family ever … this how however isn’t a “trade” for me, I truly see QNTA as a long hold investment… we just need more folks getting their eyes and subsequently their hands on the products, the products will then in turn re-sell themselves.. these are most definitely “re-order” when liked type of products… folks who habitually buy muscle rub, generally purchase and definitely repurchase when they run out … immunipen will prove to be the same situation.
Like building a snowman.., the ball of snow starts small but then grows in size exponentially…
cheers to the longs here and welcome to those new to qnta..
this OLD hair commercial comes to mind
.. “then they told two friends” and so on
He’s a good choice for promoting AELIA products (which fund research & development … ie escozine & scorpion venom) … his affect will be more telling at the end of quarters when product sales are shown … https://s-k-a-t-e-r.com/medolife-rx-signs-product-endorsement-agreement-with-legendary-skateboarder-tony-hawk/?amp=1
“Escozine® has been shown to be effective in all of the pre-clinical proof-of-concept trials we have completed and successful completion of this study will propel the program forward into Phase II clinical trials.”
https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/medolife-rx-launches-pharmacokinetic-study-110000337.html
Important points for all investors and those researching the stock!! So much good going on!!
https://ir.quantrx.com/news-events/press-releases/detail/88/medolife-rx-clarifies-april-13-2021-press-release